Page 4 - Rana Mehta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pre-produced Covishield, Covaxin in 6-month race against expiry
Both COVID-19 vaccines being administered in India s extensive vaccination programme - Serum-Oxford-AstraZeneca s Covishield and Bharat Biotech s Covaxin - have a very short shelf life of just six months
PB Jayakumar | January 27, 2021 | Updated 16:39 IST
India s coronavirus vaccination drive is faced with a new challenge - to administer the vaccines in stock before they cross their six-month expiry date.
Both Made-in-India COVID-19 vaccines being administered in the country s extensive vaccination programme - Serum-Oxford-AstraZeneca s Covishield and Bharat Biotech s Covaxin - have a very short approved shelf life of just six months. A part of this has already been spent post-production in cold storages. Serum Institute of India, for instance, was permitted by the government to pre-produce and stockpile Covishield doses starting October-November, 2020. ....

India General , Jack Muhs , Oxford Astrazeneca Covishield , Rajiv Nath , Suresh Jadhav , Rana Mehta , Serum Institute Of India , Bharat Biotech , Executive Director , Serum Institute , Business Today , Supply Chain Dynamics , Prime Minister , Drug Controller General , Managing Director , Hindustan Syringes , Middle East , Fedex Express , Pwc India , இந்தியா ஜநரல் , பலா முஹஸ் , ராஜீவ் நாத் , சுரேஷ் ஜாதவ் , ராணா மேத்தா , சீரம் நிறுவனம் ஆஃப் இந்தியா , பாரத் பயோடெக் ,